{"id":228908,"date":"2021-06-23T10:19:52","date_gmt":"2021-06-23T08:19:52","guid":{"rendered":"https:\/\/fefac.cat\/empresarial\/?p=228908"},"modified":"2021-06-23T10:24:41","modified_gmt":"2021-06-23T08:24:41","slug":"entrevista-al-president-de-fefac-a-im-farmacias-clawback","status":"publish","type":"post","link":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/","title":{"rendered":"Entrevista al presidente de FEFAC a IM Farmacias sobre el &#8216;clawback&#8217;"},"content":{"rendered":"\n<p><strong>El nuevo Plan de Fomento de Medicamentos Biosimilares y Gen\u00e9ricos recoge la introducci\u00f3n de un mecanismo de devoluci\u00f3n (<em>clawback<\/em>) al SNS de los descuentos que obtienen las<\/strong><strong><\/strong><strong>farmacias de los laboratorios por volumen de compras de gen\u00e9ricos o pronto pago. \u00bfCu\u00e1l es la opini\u00f3n de FEFAC a este respecto?<\/strong><\/p>\n\n\n\n<p>La experiencia vivida durante la pandemia provocada por la Covid-19 nos demuestra que los mecanismos de bajada de precios o de p\u00e9rdida de capacidad econ\u00f3mica conllevan inexorablemente la externalizaci\u00f3n de la producci\u00f3n y la manipulaci\u00f3n de la mayor\u00eda de las mol\u00e9culas. En situaciones como la vivida esto podr\u00eda haber sido muy grave. Desde FEFAC consideramos que hay otras pol\u00edticas mucho m\u00e1s eficientes que podr\u00edan implementarse a medio y largo plazo, como sumar a la farmacia en la prestaci\u00f3n de diferentes servicios que permitan descongestionar la atenci\u00f3n primaria, especialmente en el caso de pacientes cr\u00f3nicos y en patolog\u00edas de bajo riesgo y acciones que faciliten el cumplimiento terap\u00e9utico, la adopci\u00f3n de h\u00e1bitos saludables y la implicaci\u00f3n y participaci\u00f3n en campa\u00f1as de salud p\u00fablica que tan imprescindibles han demostrado ser, y en las que la accesibilidad y capilaridad de las farmacias es incomparable, pues el 99% de la poblaci\u00f3n tiene al menos una farmacia en su municipio.<\/p>\n\n\n\n<p>Seguir recortando en farmacia aprovechando que es el mecanismo m\u00e1s trazable de control de costes no solo no mejora nuestro sistema sanitario, sino que debilita profundamente el servicio farmac\u00e9utico, el \u00fanico que permaneci\u00f3 dando exactamente el mismo servicio a la ciudadan\u00eda durante el periodo m\u00e1s duro de la pandemia. \u00bfQu\u00e9 hubiese sucedido si, durante los meses m\u00e1s duros, las farmacias no hubiesen respondido, resuelto y aconsejado las dudas e inquietudes de la poblaci\u00f3n?<\/p>\n\n\n\n<p><strong>\u00bfQu\u00e9 consecuencias puede acarrear esta medida?<\/strong><\/p>\n\n\n\n<p>Esta medida pone en riesgo tanto la solvencia financiera de la oficina de farmacia y, como consecuencia ataca su sostenibilidad. En lugar de sumar las capacidades y oportunidades que aporta la red farmac\u00e9utica, como ya hacen muchos pa\u00edses europeos, se empobrece y debilita la respuesta que se est\u00e1 ofreciendo a la ciudadan\u00eda. No hay que olvidar, adem\u00e1s, que esta medida se suma las peri\u00f3dicas bajadas de precios de los medicamentos, a los desabastecimientos y a la despoblaci\u00f3n que afecta a la supervivencia de muchas farmacias.<\/p>\n\n\n\n<p><strong>\u00bfCu\u00e1l es la propuesta de FEFAC para fomentar el uso de los medicamentos gen\u00e9ricos?<\/strong><\/p>\n\n\n\n<p>El uso de los medicamentos biosimilares, a pesar de estar su utilidad y seguridad acreditadas, no deja de estar puesto en cuesti\u00f3n por la clase m\u00e9dica en pacientes que ya han iniciado el tratamiento con medicamentos biol\u00f3gicos de marca. En la clase m\u00e9dica no hay consenso en el hecho de cambiar el tratamiento de marca a gen\u00e9rico y la oficina de farmacia actuar\u00e1 como exige la normativa. No obstante, es bueno, tanto para el prescriptor como para el enfermo, no generar confusi\u00f3n. Por ello, no se debe descargar en la farmacia la resoluci\u00f3n de dicho conflicto.<\/p>\n\n\n\n<p>Desde FEFAC no descartamos, como hacemos siempre en los \u00e1mbitos en los que hay relaci\u00f3n con el sistema p\u00fablico, llevar a cabo acciones a nivel de la peque\u00f1a y mediana empresa, puesto que, de aplicarse a las farmacias, podr\u00eda darse tambi\u00e9n a cualquier otra relaci\u00f3n proveedor-administraci\u00f3n en el \u00e1mbito de la contrataci\u00f3n p\u00fablica, de cualquier bien o servicio, ya sea mediante concierto o no.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong><em><a rel=\"noreferrer noopener\" href=\"https:\/\/www.diariomedico.com\/farmacia\/comunitaria\/opinion\/covid-19-y-la-contribucion-de-las-farmacias.html\" target=\"_blank\"><span style=\"text-decoration: underline\">Leer <\/span><\/a><span style=\"text-decoration: underline\"><a rel=\"noreferrer noopener\" href=\"https:\/\/www.diariomedico.com\/farmacia\/comunitaria\/opinion\/covid-19-y-la-contribucion-de-las-farmacias.html\" target=\"_blank\">entrevist<\/a><a href=\"https:\/\/www.imfarmacias.es\/noticia\/24411\/seguir-recortando-en-farmacia-debilita-profundamente-el-servicio-farm.html\" target=\"_blank\" rel=\"noreferrer noopener\">a<\/a><a rel=\"noreferrer noopener\" href=\"https:\/\/www.diariomedico.com\/farmacia\/comunitaria\/opinion\/covid-19-y-la-contribucion-de-las-farmacias.html\" target=\"_blank\"> co<\/a><a rel=\"noreferrer noopener\" href=\"https:\/\/www.imfarmacias.es\/uploads\/2020\/09\/dispone_farmacia_superdotada_21537_20200910035743.pdf\" target=\"_blank\">m<\/a><a href=\"https:\/\/www.imfarmacias.es\/noticia\/21537\/se-dispone-de-una-farmacia-superdotada.html\" target=\"_blank\" rel=\"noreferrer noopener\">pleta en IM Farmacia<\/a><\/span><a rel=\"noreferrer noopener\" href=\"https:\/\/www.diariomedico.com\/farmacia\/comunitaria\/opinion\/covid-19-y-la-contribucion-de-las-farmacias.html\" target=\"_blank\"><span style=\"text-decoration: underline\">s<\/span><\/a><\/em><\/strong><\/h2>\n","protected":false},"excerpt":{"rendered":"<p>En una entrevista realitzada per IM Farmacias, el president de la FEFAC, Antoni Torres, parla del Clawback i del nou pla de foment de medicaments biosimilars i gen\u00e8rics.<\/p>\n","protected":false},"author":2313,"featured_media":228909,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2066,2075,10,11,251],"tags":[22,136,790,1748,2342],"class_list":["post-228908","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-categoria-actualitat","category-recull-de-premsa","category-empresarials","category-fefac","category-reflexions-de-junta","tag-generics","tag-medicaments","tag-biosimilars","tag-farmacs","tag-clawback"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Entrevista al president de FEFAC a IM Farmacias sobre el clawback<\/title>\n<meta name=\"description\" content=\"IM Farmacias ha entrevistat al presiden tde la FEFAC, Antoni Torres, sobre el clawback i els medicaments gener\u00eccs i biosimilars\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Entrevista al president de FEFAC a IM Farmacias sobre el clawback\" \/>\n<meta property=\"og:description\" content=\"IM Farmacias ha entrevistat al presiden tde la FEFAC, Antoni Torres, sobre el clawback i els medicaments gener\u00eccs i biosimilars\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/\" \/>\n<meta property=\"og:site_name\" content=\"FEFAC\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-23T08:19:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-06-23T08:24:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2021\/06\/antoni-torres-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1955\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"lclavijo@afb.cat\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"lclavijo@afb.cat\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\\\/\"},\"author\":{\"name\":\"lclavijo@afb.cat\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/6ac15c94fb359972b6bfa9c752486744\"},\"headline\":\"Entrevista al presidente de FEFAC a IM Farmacias sobre el &#8216;clawback&#8217;\",\"datePublished\":\"2021-06-23T08:19:52+00:00\",\"dateModified\":\"2021-06-23T08:24:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\\\/\"},\"wordCount\":621,\"image\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/antoni-torres-scaled.jpg\",\"keywords\":[\"gen\u00e8rics\",\"medicaments\",\"biosimilars\",\"f\u00e0rmacs\",\"clawback\"],\"articleSection\":[\"Actualitat\",\"Recull de premsa\",\"Empresarials\",\"FEFAC\",\"Reflexions de Junta\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\\\/\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\\\/\",\"name\":\"Entrevista al president de FEFAC a IM Farmacias sobre el clawback\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/antoni-torres-scaled.jpg\",\"datePublished\":\"2021-06-23T08:19:52+00:00\",\"dateModified\":\"2021-06-23T08:24:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/6ac15c94fb359972b6bfa9c752486744\"},\"description\":\"IM Farmacias ha entrevistat al presiden tde la FEFAC, Antoni Torres, sobre el clawback i els medicaments gener\u00eccs i biosimilars\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/antoni-torres-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/antoni-torres-scaled.jpg\",\"width\":1200,\"height\":916},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Entrevista al presidente de FEFAC a IM Farmacias sobre el &#8216;clawback&#8217;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#website\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/\",\"name\":\"FEFAC\",\"description\":\"Federaci\u00f3 d&#039;Associacions de Farm\u00e0cies de Catalunya\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/6ac15c94fb359972b6bfa9c752486744\",\"name\":\"lclavijo@afb.cat\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/author\\\/laura-2\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Entrevista al president de FEFAC a IM Farmacias sobre el clawback","description":"IM Farmacias ha entrevistat al presiden tde la FEFAC, Antoni Torres, sobre el clawback i els medicaments gener\u00eccs i biosimilars","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/","og_locale":"ca_ES","og_type":"article","og_title":"Entrevista al president de FEFAC a IM Farmacias sobre el clawback","og_description":"IM Farmacias ha entrevistat al presiden tde la FEFAC, Antoni Torres, sobre el clawback i els medicaments gener\u00eccs i biosimilars","og_url":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/","og_site_name":"FEFAC","article_published_time":"2021-06-23T08:19:52+00:00","article_modified_time":"2021-06-23T08:24:41+00:00","og_image":[{"width":2560,"height":1955,"url":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2021\/06\/antoni-torres-scaled.jpg","type":"image\/jpeg"}],"author":"lclavijo@afb.cat","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"lclavijo@afb.cat","Temps estimat de lectura":"3 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/#article","isPartOf":{"@id":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/"},"author":{"name":"lclavijo@afb.cat","@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/6ac15c94fb359972b6bfa9c752486744"},"headline":"Entrevista al presidente de FEFAC a IM Farmacias sobre el &#8216;clawback&#8217;","datePublished":"2021-06-23T08:19:52+00:00","dateModified":"2021-06-23T08:24:41+00:00","mainEntityOfPage":{"@id":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/"},"wordCount":621,"image":{"@id":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/#primaryimage"},"thumbnailUrl":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2021\/06\/antoni-torres-scaled.jpg","keywords":["gen\u00e8rics","medicaments","biosimilars","f\u00e0rmacs","clawback"],"articleSection":["Actualitat","Recull de premsa","Empresarials","FEFAC","Reflexions de Junta"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/","url":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/","name":"Entrevista al president de FEFAC a IM Farmacias sobre el clawback","isPartOf":{"@id":"https:\/\/fefac.cat\/empresarial\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/#primaryimage"},"image":{"@id":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/#primaryimage"},"thumbnailUrl":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2021\/06\/antoni-torres-scaled.jpg","datePublished":"2021-06-23T08:19:52+00:00","dateModified":"2021-06-23T08:24:41+00:00","author":{"@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/6ac15c94fb359972b6bfa9c752486744"},"description":"IM Farmacias ha entrevistat al presiden tde la FEFAC, Antoni Torres, sobre el clawback i els medicaments gener\u00eccs i biosimilars","breadcrumb":{"@id":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/#primaryimage","url":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2021\/06\/antoni-torres-scaled.jpg","contentUrl":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2021\/06\/antoni-torres-scaled.jpg","width":1200,"height":916},{"@type":"BreadcrumbList","@id":"https:\/\/fefac.cat\/empresarial\/entrevista-al-president-de-fefac-a-im-farmacias-clawback\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fefac.cat\/empresarial\/"},{"@type":"ListItem","position":2,"name":"Entrevista al presidente de FEFAC a IM Farmacias sobre el &#8216;clawback&#8217;"}]},{"@type":"WebSite","@id":"https:\/\/fefac.cat\/empresarial\/#website","url":"https:\/\/fefac.cat\/empresarial\/","name":"FEFAC","description":"Federaci\u00f3 d&#039;Associacions de Farm\u00e0cies de Catalunya","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fefac.cat\/empresarial\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/6ac15c94fb359972b6bfa9c752486744","name":"lclavijo@afb.cat","url":"https:\/\/fefac.cat\/empresarial\/author\/laura-2\/"}]}},"_links":{"self":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts\/228908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/users\/2313"}],"replies":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/comments?post=228908"}],"version-history":[{"count":0,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts\/228908\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/media\/228909"}],"wp:attachment":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/media?parent=228908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/categories?post=228908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/tags?post=228908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}